We had initiated our study based on the hypothesis that strong activation of the PI3K/AKT pathway mimics excessive signaling strength from an autoreactive BCR and that this may be leveraged to trigger negative selection for therapeutic benefit in CLL patients. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.